Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.

@article{Fukushima2012Daily5M,
  title={Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.},
  author={Toshihiro Fukushima and Tomomi Sato and Takuji Nakamura and Haruka Iwao and Akio Nakajima and Miyuki Miki and Tomoyuki Sakai and Takafumi Kawanami and Toshioki Sawaki and Yoshimasa Fujita and Masao Tanaka and Yasufumi Masaki and Toshiro Okazaki and Hideo Nakajima and Yoshiharu Motoo and Hisanori Umehara},
  journal={Anticancer research},
  year={2012},
  volume={32 12},
  pages={5437-40}
}
BACKGROUND In patients with multiple myeloma (MM), bortezomib is associated with a significant risk of Varicella zoster virus (VZV) reactivation. There are some reports that acyclovir reduces the risk of VZV reactivation. We assessed whether VZV reactivation could be reduced by using prophylactic valacyclovir at a dose of 500 mg daily. PATIENTS AND METHODS We retrospectively evaluated 32 patients with MM who received bortezomib and valacyclovir prophylaxis at the Kanazawa Medical University… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS